• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    China Reinsurance (SEHK:1508) Stock Looks Cheap Despite Mixed Profit Momentum

    Simply Wall St·08/30/2026 00:28:13
    语音播报

    China Reinsurance (Group) stock has slipped over the past month and the latest close at HK$1.235 leaves it valued on a very low P/E near 4x. Yet H1 2026 delivered solid underwriting and investment progress, with basic earnings per share of ¥0.17 and net income of ¥7,186.997m. The headline today is simple: the market is treating China Reinsurance like a structurally troubled insurer while the latest half year shows earnings power that does not obviously match that level of pessimism.

    Is China Reinsurance (Group) trading at a genuine bargain P/E near 4x, or does the recent margin picture justify the discount? See how the current price lines up against fundamentals in our valuation analysis for China Reinsurance (Group)

    H1 2026 Earnings Summary

    • Revenue (H1 2026 vs H1 2025): ¥56,548.667m vs. ¥53,017.005m (change of about 6.7%)
    • Net Income (Excl. Extra Items, H1 2026 vs H1 2025): ¥7,186.997m vs. ¥6,243.749m (change of about 15.1%)
    • Basic EPS (H1 2026 vs H1 2025): ¥0.17 per share vs. ¥0.146981 per share (change of about 15.7%)
    • Trailing 12M Net Income (Excl. Extra Items, H1 2026 TTM vs H1 2025 TTM): ¥10,714.391m vs. ¥11,073.955m (change of about 3.2%)

    Prefer clean charts over a dense wall of earnings figures and ratios? See China Reinsurance (Group)'s full financial picture, including how the valuation compares with its recent profit record, in the visual company report for China Reinsurance (Group).

    SEHK:1508 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    SEHK:1508 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    China Reinsurance’s Earnings Do Some Heavy Lifting For The Bull Case

    The optimistic case for China Reinsurance says that better technology and global scale will translate into stronger underwriting and earnings power. The latest half year offers some concrete milestones in that direction. Revenue for H1 2026 is higher than H1 2025, and net income excluding extra items and basic EPS also move up, which indicates that growth is not just coming through the top line.

    For a reinsurer, underwriting quality and earnings consistency matter more than headline volume. Here, China Reinsurance shows a mixed picture. The trailing 12 month net income excluding extra items is slightly below the prior year period, so the stronger half year has not yet fully rebuilt longer run profit momentum. That indicates progress on the technology and integration story, but not yet clear evidence that these changes are lifting earnings on a sustained, through the cycle basis.

    Compare this earnings progress with how the street is framing China Reinsurance’s story. See the consensus price target analysis for China Reinsurance (Group) to check whether analysts think the stock’s current HK$1.235 price reflects that operational shift or still prices in a deeper risk discount.

    China Reinsurance Bear Case: Progress, But Key Risks Linger

    The bearish view says China Reinsurance is structurally exposed to volatile catastrophe losses, pressured margins and China heavy investment risk that earnings cannot offset. The latest H1 2026 numbers soften that story but do not fully overturn it. Revenue and net income excluding extra items are higher than H1 2025 and basic EPS is up, which challenges the idea that the business is stuck in a margin squeeze. However, trailing 12 month net income excluding extra items is below the prior period, so the stronger half year has not yet rebuilt a clear trend of earnings resilience.

    Bears also worry that execution on technology and overseas expansion will not show up in steadier profits. Here, there is no clean milestone yet. The interim results show progress, but they do not yet prove that climate exposure, China concentration and capital pressures are firmly under control through the cycle.

    After an earnings lift in H1 2026, are catastrophe exposure and an unstable dividend record hinting at deeper issues? Review the full risk analysis for China Reinsurance (Group) which shows 1 important warning sign

    Take Control Of Your Next Move

    If China Reinsurance (Group)'s low P/E and recent H1 2026 earnings progress have caught your attention, register for free with Simply Wall St and add it to a Watchlist to keep track of price versus fair value and wait for a level that fits your plan. Once you are invested, use the Portfolio Command Center to cut through market noise and focus on the key updates that matter to your holdings. For a wider lens, turn to the Community to see how other investors are interpreting the same data and risks. This way you can spot potential catalysts or warning signs early and stay a step ahead of the market.

    Seeking Alternatives Beyond China Reinsurance?

    Fresh ideas move first, not last. Spot potential breakout stories and building momentum while they are still under the radar for now. Do not get caught dropping behind. Consider taking action after careful research.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.